Clinical efficacy for RA treatment with Adalimumab

Abstract

Objective: We investigate the optimal clinical use of Adalimumab (ADA) for RA patients who resisted prior DMARDs therapy.
Patients and methods: In 2009-2010, 55 RA patients were treated with ADA for 24 weeks in Kinki University RA groups (open label and multi center).
Results: At 24 weeks, we evaluated 53 RA patients to find good response 14 (26%), moderate response 25 (in total 73.6%), unchanged or poor 9,unevaluated 5. The final remission rate increased the DAS to 22.4% and CDAI to 19.0%.In the LOCF analysis, DAS 28 decreased from 5.23 to 3.66.Clinical results were good in Bio naïve and MTX combination groups.
Conclusion: The optimal uses of ADA for RA treatment, are bio-naïve cases and using with the MTX.